Azenosertib (also known as ZN-c3; KP-2638)

DRUG3 trials

Sponsors

K-Group Beta Inc.

Conditions

Fallopian TubeHigh-Grade Serous OvarianPlatinum-Resistant Ovarian Cancemetastatic colorectal canceror Primary Peritoneal Cancer

Phase 1

Z0011001-A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF ZN-c3 ADMINISTERED IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN ADULTS WITH METASTATIC COLORECTAL CANCER

CompletedCTIS2022-502267-37-00

K-Group Beta Inc.metastatic colorectal cancer

Start: 2023-07-17End: 2025-11-24Target: 50Updated: 2025-06-03

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib and ZN-c3 Monotherapy in Subjects with Platinum-resistant Ovarian Cancer.

RecruitingCTIS2024-515196-35-00

K-Group Beta Inc.Platinum-Resistant Ovarian Cance

Start: 2022-09-29Target: 150Updated: 2026-01-06

Phase 2

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN‑c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

RecruitingCTIS2022-502983-19-00

K-Group Beta Inc.Fallopian Tube, High-Grade Serous Ovarian, or Primary Peritoneal Cancer

Start: 2025-07-31Target: 137Updated: 2026-01-22